Skip NavigationSkip to Content

NCI at Frederick Scientific Publications Advanced Search

Search

  1. NCI-F Publications

  2. Return to Quick Search
Search
  2. Year Published:

Your search returned 31 results.
User Information
Export Records
  1. 1.   Novel Arf1 Inhibitors Drive Cancer Stem Cell Aging and Potentiate Anti-Tumor Immunity
  2. Wang, Yuetong; Li, Qiaoming; Ding, Yahui; Luo, Chenfei; Yang, Jun; Wang, Na; Jiang, Ning; Yao, Tiange; Wang, Guohao; Shi, Guoming; Hou, Steven X
  3. Advanced Science (Weinheim, Baden-Wurttemberg, Germany). 2024, Sep 03; e2404442.
  1. 2.   Divergent HLA variations and heterogeneous expression but recurrent HLA loss-of- heterozygosity and common HLA-B and TAP transcriptional silencing across advanced pediatric solid cancers
  2. Lim, Wan Ching; Marques Da Costa, Maria Eugenia; Godefroy, Karine; Jacquet, Eric; Gragert, Loren; Rondof, Windy; Marchais, Antonin; Nhiri, Naima; Dalfovo, Davide; Viard,Mathias; Labaied, Nizar; Khan, Asif M; Dessen, Philippe; Romanel, Alessandro; Pasqualini, Claudia; Schleiermacher, Gudrun; Carrington,Mary; Zitvogel, Laurence; Scoazec, Jean-Yves; Geoerger, Birgit; Salmon, Jerome
  3. Frontiers in Immunology. 2024, Jan 22; 14: 1265469.
  1. 3.   High-mobility group nucleosome binding domain 1 (HMGN1) functions as a Th1-polarizing alarmin
  2. Yang, De; Han, Zhen; Alam, Md Masud; Oppenheim, Joost
  3. Seminars in immunology. 2018, Mar 01; pii: S1044-5323(17)30075-1.
  1. 4.   Alarmins and immunity
  2. Yang, De; Han, Zhen; Oppenheim, Joost
  3. Immunological Reviews. 2017, Nov; (1): 41-56.
  1. 5.   Intratumoral Injection of CpG Oligonucleotides Induces the Differentiation and Reduces the Immunosuppressive Activity of Myeloid-Derived Suppressor Cells
  2. Shirota, Y.; Shirota, H.; Klinman, D. M.
  3. Journal of Immunology. 2012, Feb; 188(4): 1592-1599.
  1. 6.   Tumor-Specific CD8(+) T Cells Expressing Interleukin-12 Eradicate Established Cancers in Lymphodepleted Hosts
  2. Kerkar, S. P.; Muranski, P.; Kaiser, A.; Boni, A.; Sanchez-Perez, L.; Yu, Z. Y.; Palmer, D. C.; Reger, R. N.; Borman, Z. A.; Zhang, L.; Morgan, R. A.; Gattinoni, L.; Rosenberg, S. A.; Trinchieri, G.; Restifo, N. P.
  3. Cancer Research. 2010, Sep; 70(17): 6725-6734.
  1. 7.   Toll-like Receptor 9 Activation of Signal Transducer and Activator of Transcription 3 Constrains Its Agonist-Based Immunotherapy
  2. Kortylewski, M.; Kujawski, M.; Herrmann, A.; Yang, C. M.; Wang, L.; Liu, Y.; Salcedo, R.; Yu, H.
  3. Cancer Research. 2009 69(6): 2497-2505.
  1. 8.   Cutting Edge: Tumor-Specific CD8(+) T Cells Infiltrating Prostatic Tumors Are Induced to Become Suppressor Cells
  2. Shafer-Weaver, K. A.; Anderson, M. J.; Stagliano, K.; Malyguine, A.; Greenberg, N. M.; Hurwitz, A. A.
  3. Journal of Immunology. 2009 183(8): 4848-4852.
  1. 9.   Immunity to Murine Prostatic Tumors: Continuous Provision of T-Cell Help Prevents CD8 T-Cell Tolerance and Activates Tumor-Infiltrating Dendritic Cells
  2. Shafer-Weaver, K. A.; Watkins, S. K.; Anderson, M. J.; Draper, L. J.; Malyguine, A.; Alvord, W. G.; Greenberg, N. M.; Hurwitz, A. A.
  3. Cancer Research. 2009 69(15): 6256-6264.
  1. 10.   Tumor-specific Th17-polarized cells eradicate large established melanoma
  2. Muranski, P.; Boni, A.; Antony, P. A.; Cassard, L.; Irvine, K. R.; Kaiser, A.; Paulos, C. M.; Palmer, D. C.; Touloukian, C. E.; Ptak, K.; Gattinoni, L.; Wrzesinski, C.; Hinrichs, C. S.; Kerstann, K. W.; Feigenbaum, L.; Chan, C. C.; Restifo, N. P.
  3. Blood. 2008 112(2): 362-373.
  1. 11.   Phenotype and functional characterization of long-term gp100-specific memory CD8(+) T cells in disease-free melanoma patients before and after boosting immunization
  2. Walker, E. B.; Haley, D.; Petrausch, U.; Floyd, K.; Miller, W.; Sanjuan, N.; Alvord, G.; Fox, B. A.; Urba, W. J.
  3. Clinical Cancer Research. 2008 14(16): 5270-5283.
  1. 12.   Transduction of the gene coding for a human G-protein coupled receptor FPRL1 in mouse tumor cells increases host anti-tumor immunity
  2. Hu, J. Y.; Li, G. C.; Tong, Y. Q.; Li, Y. H.; Zhou, G. H.; He, X. J.; Xie, P. L.; Wang, J. M.; Sun, Q. B.
  3. International Immunopharmacology. 2005, JUN; 5(6): 971-980.
  1. 13.   Constitutive expression of functional CD40 on mouse renal cancer cells: Induction of Fas and Fas-mediated killing by CD40L
  2. Lee, J. K.; Seki, N.; Sayers, T. J.; Subleski, J.; Gruys, E. M.; Murphy, W. J.; Wiltrout, R. H.
  3. Cellular Immunology. 2005, JUN; 235(2): 145-152.
  1. 14.   Mouse Ly49 NK receptors: balancing activation and inhibition
  2. Ortaldo, J. R.; Young, H. A.
  3. Molecular Immunology. 2005, FEB; 42(4): 445-450.
  1. 15.   IL-27 mediates complete regression of orthotopic primary and metastatic murine neuroblastoma tumors: Role for CD8(+) T cells
  2. Salcedo, R.; Stauffer, J. K.; Lincoln, E.; Back, T. C.; Hixon, J. A.; Hahn, C.; Shafer-Weaver, K.; Malyguine, A.; Kastelein, R.; Wigginton, J. M.
  3. Journal of Immunology. 2004, DEC 15; 173(12): 7170-7182.
  1. 16.   Chemokine receptor-mediated delivery directs self-tumor antigen efficiently into the class II processing pathway in vitro and induces protective immunity in vivo
  2. Biragyn, A.; Ruffini, P. A.; Coscia, M.; Harvey, L. K.; Neelapu, S. S.; Baskar, S.; Wang, J. M.; Kwak, L. W.
  3. Blood. 2004, OCT 1; 104(7): 1961-1969.
  1. 17.   Therapeutic idiotype vaccines in B lymphoproliferative diseases
  2. Coscia, M.; Kwak, L. W.
  3. Expert Opinion on Biological Therapy. 2004 4(6): 959-963.
  1. 18.   Structure and characterization of hamster IL-12 p35 and p40
  2. Maruyama, K.; Takigawa, Y.; Akiyama, Y.; Hojo, T.; Nara-Ashizawa, N.; Cheng, J. Y.; Watanabe, M.; Yamaguchi, K.
  3. Molecular Immunology. 2003 40(6): 319-326.
  1. 19.   Tumour-induced polarization of tumour vaccine-draining lymph node T cells to a type 1 cytokine profile predicts inherent strong immunogenicity of the tumour and correlates with therapeutic efficacy in adoptive transfer studies
  2. Winter, H.; Hu, H. M.; Poehlein, C. H.; Huntzicker, E.; Osterholzer, J. J.; Bashy, J.; Lashley, D.; Lowe, B.; Yamada, J.; Alvord, G.; Urba, W. J.; Fox, B. A.
  3. Immunology. 2003 108(3): 409-419.
  1. 20.   Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells
  2. Overwijk, W. W.; Theoret, M. R.; Finkelstein, S. E.; Surman, D. R.; de Jong, L. A.; Vyth-Dreese, F. A.; Dellemijn, T. A.; Antony, P. A.; Spiess, P. J.; Palmer, D. C.; Heimann, D. M.; Klebanoff, C. A.; Yu, Z. Y.; Hwang, L. N.; Feigenbaum, L.; Kruisbeek, A. M.; Rosenberg, S. A.; Restifo, N. P.
  3. Journal of Experimental Medicine. 2003 198(4): 569-580.
  1. 21.   DNA vaccines encoding human immunodeficiency virus-1 glycoprotein 120 fusions with proinflammatory chemoattractants induce systemic and mucosal immune responses
  2. Biragyn, A.; Belyakov, I. M.; Chow, Y. H.; Dimitrov, D. S.; Berzofsky, J. A.; Kwak, L. W.
  3. Blood. 2002 100(4): 1153-1159.
  1. 22.   Toll-like receptor 4-dependent activation of dendritic cells by beta-defensin 2
  2. Biragyn, A.; Ruffini, P. A.; Leifer, C. A.; Klyushnenkova, E.; Shakhov, A.; Chertov, O.; Shirakawa, A. K.; Farber, J. M.; Segal, D. M.; Oppenheim, J. J.; Kwak, L. W.
  3. Science. 2002 298(5595): 1025-1029.
  1. 23.   Recent advances in multiple myeloma immunotherapy
  2. Ruffini, P. A.; Biragyn, A.; Kwak, L. W.
  3. Biomedicine and Pharmacotherapy. 2002 56(3): 129-132.
  1. 24.   Mammalian defensins in immunity: more than just microbicidal
  2. Yang, D.; Biragyn, A.; Kwak, L. W.; Oppenheim, J. J.
  3. Trends in Immunology. 2002 23(6): 291-296.
  1. 25.   Idiotypic vaccination for B-cell malignancies as a model for therapeutic cancer vaccines: from prototype protein to second generation vaccines
  2. Ruffini, P. A.; Neelapu, S. S.; Kwak, L. W.; Biragyn, A.
  3. Haematologica-the Hematology Journal. 2002 87(9): 989-1001.
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel